-DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients

Press/Media: Press / Media

PeriodNov 16 2020

Media coverage

1

Media coverage

  • Title-DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients
    Media name/outletENP Newswire
    Date11/16/20
    PersonsEric J Lawitz